Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.88 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.77 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | PI4KA | P42356 | 2/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.67 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.67 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9484927 | 1.00 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL23228230 | 1.00 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL1741560 | 1.00 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL4551803 | 0.98 | ADORA2A (0.91) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL28176129 | 0.97 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL28228476 | 0.97 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL1074972 | 0.94 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL8252223 | 0.89 | ADORA2A (0.75) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL8207464 | 0.89 | ADORA2A (0.75) | ADORA2AADORA1ADORA2BALDH1A1PI4KA | |
| SCHEMBL29387721 | 0.87 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BALDH1A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-12 | — | — | US | disclosed |
| US-20210106606-A1 | USE OF NAD PRECURSORS FOR IMPROVING MATERNAL HEALTH AND/OR OFFSPRING HEALTH | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2021-04-15 | — | — | US | disclosed |
| US-10954257-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200385725-A1 | UNA AMIDITES AND USES THEREOF | Atrium Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, IRF3 | ADORA2A 225/4885ADORA1 247/4885ADORA2B 241/4885 |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | ADORA2A 1343/4885ADORA1 762/4885ADORA2B 1411/4885 |
| US-20210106606-A1 | USE OF NAD PRECURSORS FOR IMPROVING MATERNAL HEALTH AND/OR OFFSPRING HEALTH | NQO1, NNT, SIRT3 | ADORA2A 473/4885ADORA1 607/4885ADORA2B 557/4885 |
| US-20200385725-A1 | UNA AMIDITES AND USES THEREOF | NCL, PNP, NASP | ADORA2A 1151/4885ADORA1 1005/4885ADORA2B 842/4885 |
| US-10954257-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | ADORA2A 1343/4885ADORA1 762/4885ADORA2B 1411/4885 |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | ADORA2A 900/4885ADORA1 1640/4885ADORA2B 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.